Suppression of Atherogenesis in Cholesterol-fed Rabbit Treated with Nifedipine

PHILIP D. HENRY and KAREN I. BENTLEY, Cardiovascular Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110

ABSTRACT We tested the effects of nifedipine, a calcium antagonist, on atherogenesis in rabbits fed a 2% cholesterol diet. The drug was given orally, 40 mg/dl, and control rabbits received placebo. Nifedipine was well tolerated, and evoked only transient, moderate reductions in arterial pressure. Plasma total cholesterol after 8 wk before killing the rabbits was similar in the placebo and nifedipine-treated groups, averaging 1,903±138 (n = 13) and 1,848±121 mg/dl (n = 13; mean±SE; P > 0.8). In placebo-treated rabbits, aortic lesions stainable with Sudan IV covered 40±5% of the intimal surface, and the cholesterol concentration in aortic tissue was 47±5 mg/g protein. Corresponding values for the aortas from nifedipine-treated rabbits were significantly lower and averaged 17±3% (P < 0.001) and 29±2 mg/g protein (P < 0.001). We conclude that nifedipine suppressed atherogenesis without reducing hypercholesterolemia.

INTRODUCTION

Current evidence suggests that calcium may play a pathogenic role in atherosclerosis (1–7). In cholesterol-fed rabbits, anticalcifying and hypocalcemic agents such as diphosphonates (2–5), thiophene compounds (6), and EDTA (7) have been demonstrated to exert antitherogenic effects without reducing the diet-induced hypercholesterolemia. In this report, we show that nifedipine suppresses atherogenesis in choles-

Address correspondence to Dr. Philip D. Henry, Department of Medicine (Cardiology), Washington University School of Medicine, St. Louis, Mo. 63110.

Received for publication 23 July 1981 and in revised form 11 August 1981.

rapid

publications

J. Clin. Invest. © The American Society for Clinical Investigation, Inc. 0021-9738/81/11/1366/04 $1.00

Volume 68 November 1981 1366–1369

56 male white New Zealand rabbits from a single vendor (Boswell’s Bunny Farm, Pacific, Mo.) weighing 2.3–2.6 kg were housed individually under controlled conditions and randomly assigned to four equal diet and treatment groups: (a) standard pellets and placebo, (b) standard pellets and nifedipine, (c) 2% cholesterol pellets (Nutritional Biochemicals, Cleveland, Ohio) and placebo, and (d) 2% cholesterol pellets and nifedipine. The daily amount of pellets was 100 g for all rabbits, and water was given ad lib. Nifedipine was force-fed, two 10-mg capsules at 7 a.m. and 7 p.m. (40 mg/d), and untreated rabbits received identical capsules without nifedipine (placebo). In each group, five rabbits were selected randomly for the study of arterial pressure during the first and last week of the diet period. A No. 21 pediatric needle was inserted into the central ear artery and taped to the ear (11). Without restraining the rabbit, the needle was intermittently connected to a Gould P23 Db pressure transducer (Gould Inc., Instruments Div., Cleveland, Ohio), which was placed at mid-chest level and attached to a Gould amplifier/ recorder system. At the beginning and at the end of the diet period, blood samples were collected from the central ear artery of all rabbits into tubes containing Na2EDTA (1 μg/100 μl). The samples were used for the determination of the microhematocrit, and the separated plasma was analyzed for total cholesterol, triglycerides, phosphate, total protein, and albumin with a Gemini automatic analyzer (Electro-Nucleonics, Inc., Fairfield, N.J.). Plasma calcium was measured by atomic absorption spectrophotometry (see below). The rabbits were killed after 8 wk. The thoracic aorta
RESULTS

Two cholesterol-fed rabbits, one receiving placebo, the other nifedipine, died of unknown cause during the diet period. Values for body weight, hematocrit, and biochemical measurements in plasma are summarized in Table I. Plasma cholesterol and triglyceride levels in cholesterol-fed rabbits given placebo or nifedipine were similar.

Effects of nifedipine and placebo on mean arterial pressure and heart rate during the 1st wk of cholesterol feeding are shown in Fig. 1. After each dose of nifedipine, mean arterial pressure decreased maximally by 10–12 mm Hg (P < 0.001), and returned to control values within <2 h. Responses in the same rabbits at the end of the diet period were not significantly different from those elicited during the 1st wk (P > 0.5), and values in control rabbits given nifedipine or placebo did not differ from those obtained in cholesterol-fed rabbits receiving the corresponding treatment (P > 0.5 for all values).

In cholesterol-fed rabbits, the percentage of the intimal surface covered by Sudan-positive lesions averaged 40±5% (SE) in placebo-treated rabbits (n = 13), and 17±3% in nifedipine-treated rabbits (n = 13; P < 0.001). The cholesterol concentrations in aortas from rabbits given standard pelleted were 6.1±0.3 mg/g protein for the placebo group, and 6.3±0.4 mg/g protein for the nifedipine group. In cholesterol-fed rabbits,

<table>
<thead>
<tr>
<th>Table I</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body Weight, Hematocrit, and Plasma Constituents</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Body weight, g</td>
</tr>
<tr>
<td>Hematocrit, vol %</td>
</tr>
<tr>
<td>Total cholesterol, mg/dl</td>
</tr>
<tr>
<td>Triglycerides, mg/dl</td>
</tr>
<tr>
<td>Total calcium, mg/dl</td>
</tr>
<tr>
<td>Phosphorus, mg/dl</td>
</tr>
<tr>
<td>Total protein, g/dl</td>
</tr>
<tr>
<td>Albumin, g/dl</td>
</tr>
</tbody>
</table>

Values (means±SE) refer to measurements obtained at the end of the diet period. Values at the onset of the period, indicated in parentheses, are given only if they differed from the subsequent values (P < 0.05, paired t test). Simultaneous comparisons among the four groups (analysis of variance, see Methods) revealed significant differences only between cholesterol groups and standard diet groups (values with *: P < 0.001).
values for the placebo and nifedipine groups differed significantly ($P < 0.001$), averaging $47.5 \pm 2$ and $29.2 \pm 2$ mg/g protein. Treatment with nifedipine altered the relationship between aortic cholesterol accumulation and formation of Sudan-positive lesions. The ratio relating planimetered lesions (percent) to tissue cholesterol (milligrams per gram protein) averaged $0.85 \pm 0.05$ and $0.58 \pm 0.04\%/(mg/g$ protein) in untreated and treated rabbits ($P < 0.001$). In rabbits given standard diet, calcium concentrations in aortic tissue for the placebo and nifedipine groups were $190 \pm 11$ and $194 \pm 14 \mu g/g$ protein. In cholesterol-fed rabbits, aortic calcium for the nifedipine group was significantly lower than that for the placebo group, values averaging $202 \pm 14$ and $297 \pm 18 \mu g/g$ protein ($P < 0.005$). Microscopic evaluation of aortic tissue revealed qualitatively similar lesions in the two cholesterol-fed groups, but a quantitative structural analysis was not performed in this study.

**DISCUSSION**

Calcium overload as a pathogenic mechanism of cell injury has been incriminated in various disorders of cardiac and skeletal muscle including catecholamine-induced cardiac necrosis (8, 13), myocardial ischemia (8, 13), myopathies (9, 17), and malignant hyperthermia (18). Of interest is that in the majority of these pathophysiological entities calcium antagonists effectively suppress calcium accumulation and cell necrosis (8, 13, 17, 18). Moreover, myopathic Syrian hamsters given a calcium-deficient diet exhibit fewer lesions in skeletal and cardiac muscle (17). Conversely, facilitation of calcium uptake with ionophores or membrane-active toxins such as lyso phospholipids or macrolide antibiotics accelerate necrosis of isolated skeletal muscle (19) and rat hepatocytes in culture (10).

Studies showing protective effects of calcium antagonists in syndromes associated with membrane injury, calcium overload, and cell necrosis may partly explain the antiatherogenic activity of nifedipine. Atherogenesis is accompanied by an accumulation of calcium in arterial walls (1–7), and proliferation of smooth muscle cells, a key process in lesion formation, goes hand in hand with cell necrosis (20, 21). Necrosis of foam cells releasing membrane-active lipid, such as cholesterol, may affect the membranes of neighboring cells and accelerate cellular deterioration and turnover.Decreased necrosis associated with intracellular retention of lipid may explain why lesion formation for a given lipid accumulation was significantly decreased in nifedipine-treated rabbits. We have previously demonstrated that a high cholesterol environment sensitizes isolated arteries to the constrictor effects of calcium, consistent with increased calcium uptake after acquisition of membrane cholesterol (22, 23).

Although nifedipine may influence proliferating smooth muscle, the drug may act by other mechanisms. Arterial pressure is an important determinant of atherogenesis, and elevated pressure aggravates atherosclerosis in cholesterol-fed rabbits (11). Therefore, vasodilator-induced hypotension might exert protective effects, although hypotensive responses were not sustained in this study. Moreover, potent vasodilators such as nifedipine might influence arteries by increasing vasa vasorum flow (24). Calcium antagonists may act on platelets. However, nifedipine does not appear to have antiaggregating effects on human platelets (25, 26), and the action of verapamil and diltiazem on platelets occur only at high concentrations known to exert nonspecific effects (8, 26, 27).

Since calcium antagonists are used extensively for the treatment of coronary artery disease (8), the present study has potential clinical implications. Unlike anticalcifying drugs (2–7), calcium antagonists are not known to affect bone mineralization, and might be evaluated in children with familial hypercholesterolemia.

**ACKNOWLEDGMENT**

We thank Cynthia Lucas and Malcolm Clark for excellent assistance, and Barbara Donnelly and Helen Nikolaisen for the preparation of the manuscript. We also thank Dr. Ken Schechman, Department of Biostatistics, Washington University, for the statistical analyses, and Dr. Joseph William-son, Department of Pathology, Washington University, for the
computerized planimetry. We are indebted to Dr. Stanley Fishman and Dr. David Poorvin for their support and making nifedipine (Pfizer Pharmaceuticals, Pfizer Inc., New York) available to us.

This work was supported in part by grants HL 21187; SCOR HL 17646 from the National Institutes of Health.

REFERENCES


Nifedipine and Atherogenesis 1369